Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly ADP Ribose Polymerase (PARP) Inhibitor”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Testing effectiveness (Phase 2)Study completedNCT03326193
What this trial is testing

Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 105
Early research (Phase 1)WithdrawnNCT04149145
What this trial is testing

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
University of Alabama at Birmingham
Early research (Phase 1)WithdrawnNCT02686008
What this trial is testing

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Yale University
Testing effectiveness (Phase 2)Study completedNCT03574779
What this trial is testing

Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 77
Early research (Phase 1)Study completedNCT01009190
What this trial is testing

Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Who this might be right for
Advanced Solid Tumors
pharmaand GmbH 85
Testing effectiveness (Phase 2)Study completedNCT00271765
What this trial is testing

INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Who this might be right for
Acute Myocardial Infarction
Inotek Pharmaceuticals Corporation 40
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Large-scale testing (Phase 3)Looking for participantsNCT07472140
What this trial is testing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre 120
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Early research (Phase 1)Study completedNCT00387608
What this trial is testing

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Who this might be right for
LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC) 23
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)Active Not RecruitingNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Testing effectiveness (Phase 2)Study completedNCT01063517
What this trial is testing

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Who this might be right for
Gastric Cancer
AstraZeneca 124
Testing effectiveness (Phase 2)Study completedNCT05751629
What this trial is testing

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
Tesaro, Inc. 41
Load More Results